Search Results for "Cytotec"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for Cytotec. Results 1 to 4 of 4 total matches.
See also: misoprostol
In Brief: Alternatives to Mifepristone for Medication Abortion
The Medical Letter on Drugs and Therapeutics • Jun 26, 2023 (Issue 1679)
(Cytotec, and
generics). The regimen, which consists of a single
oral 200-mg dose of mifepristone ...
The possibility that use of mifepristone (Mifeprex,
and generics) may be restricted has led to questions
about alternatives for medication abortion.
Med Lett Drugs Ther. 2023 Jun 26;65(1679):102-3 doi:10.58347/tml.2023.1679d | Show Introduction Hide Introduction
In Brief: Mifepristone by Mail for Pregnancy Termination
The Medical Letter on Drugs and Therapeutics • Jan 24, 2022 (Issue 1642)
with
the prostaglandin E1 analog misoprostol (Cytotec,
and generics) for medical termination of pregnancy,
must ...
The FDA has removed the requirement that
mifepristone (Mifeprex, and generics), a progestin
receptor antagonist approved for use in a regimen with
the prostaglandin E1 analog misoprostol (Cytotec,
and generics) for medical termination of pregnancy,
must be dispensed in person to the patient.
In Brief: Expanded Heart Failure Indication for Dapagliflozin (Farxiga)
The Medical Letter on Drugs and Therapeutics • Jun 26, 2023 (Issue 1679)
Cytotec (Pfizer) 800 mcg buccally 24-48 hrs 23.20
after mifepristone
Alone:
800 mcg buccally ...
The sodium-glucose cotransporter 2 (SGLT2)
inhibitor dapagliflozin (Farxiga – AstraZeneca) was
approved by the FDA in 2020 to reduce the risk of
cardiovascular death and hospitalization for heart
failure (HF) in adults with heart failure with reduced
ejection fraction (HFrEF). The indication has now
been expanded to include a reduction in the risk
of urgent HF visits and use in adults with any left
ventricular ejection fraction (LVEF).
Med Lett Drugs Ther. 2023 Jun 26;65(1679):101-2 doi:10.58347/tml.2023.1679c | Show Introduction Hide Introduction
Drugs for GERD and Peptic Ulcer Disease
The Medical Letter on Drugs and Therapeutics • Apr 04, 2022 (Issue 1647)
82.50
Cytotec (Pfizer) 345.80
Sucralfate18 – generic 1 g tabs; 1 g/10 mL susp 1 g PO qid19 36.00 ...
Gastroesophageal reflux disease (GERD) is the most
common GI condition encountered in the outpatient
setting; it affects about 20% of people in the US.